| Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. | leukemia, |
| This review summarizes the role of Ikaros (IKZF1) in tumor suppression and regulation of gene expression in leukemia. | leukemia, |
| Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia | leukemia, |
| Phosphorylation of Ikaros by CK2 impairs Ikaros DNA-binding ability, as well as Ikaros ability to regulate gene expression and function as a tumor suppressor in leukemia. (Review) | leukemia, |
| Evidence was provided that Ikaros possesses the properties of a bona fide tumor suppressor gene for the T-cell lineage. | None |
| identify IKAROS-mediated cell cycle exit as the endpoint of an emerging pathway of pre-B cell receptor-mediated tumor suppression | None |
| Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. | leukemia, |
| these results suggest that loss of IKZF1 is recurrent in pediatric acute myeloid leukemia and might be a determinant of oncogenesis in acute myeloid leukemia with monosomy 7. | leukemia,pediatric, |
| Data indicate an oncogenic role for an Ikaros protein/MYCBP2 protein/proto-oncogene protein c-MYC axis in adult acute lymphoblastic leukemia (ALL), providing a mechanism of target therapies that activate Ikaros in ALL. | leukemia, |
| high CRLF2 expression works with the IKZF1 deletion to drive oncogenesis of acute lymphoblastic leukemia | leukemia, |